HAGENS BERMAN Encourages ChemoCentryx (CCXI) Investors with Losses to Contact the Firm Now, Securities Fraud Lawsuit Pending
SAN FRANCISCO, May 31, 2021 (GLOBE NEWSWIRE) — Hagens Berman urges ChemoCentryx, Inc.
(NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pending and certain investors may have valuable claims.
Class Period: Nov. 26, 2019 – May 3, 2021
Lead Plaintiff Deadline: July 6, 2021
Visit: www.hbsslaw.com/investor-fraud/CCXI
844-916-0895
ChemoCentryx, Inc. (NASDAQ: CCXI) Securities Fraud Class Action:
The lawsuit focuses on ChemoCentryx’s statements about its new drug application (“NDA”) for its vasculitis drug candidate Avacopan.
Beginning on Nov. 25, 2019, ChemoCentryx touted positive topline data from its Pivotal Phase III ADVOCATE trial demonstrating Avacopan’s superiority over standard of care in ANCA-associated vasculitis and that the trial met both of its primary endpoints. This and subsequent positive announcements sent the price of CCXI soaring.